businesspress24.com - Functional Technologies Grants Options
 

Functional Technologies Grants Options

ID: 1028233

(firmenpresse) - VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 08/08/11 -- Functional Technologies Corp. (TSX VENTURE: FEB) (the "Company") today reported the grant of stock options to its directors for the purchase of a total of 750,000 common shares. The options are exercisable for five years at a price of $0.60 per share. The last grant of options to directors was made in September 2009.

About Functional Technologies Corp.

Functional Technologies develops and commercializes proprietary, advanced yeast-based solutions to significant challenges in the food, beverage and healthcare industries. The Company's platform improves the performance of innate yeast functions, and prevents the formation of naturally occurring toxins and contaminants that either affect final product quality or are classified by the World Health Organization as probable human carcinogens. Functional Technologies' lead technologies include yeasts that prevent and reduce the formation of the foul-smelling hydrogen sulphide (H2S) and the carcinogens acrylamide and ethyl carbamate (more commonly known as urethane), by-products of food and beverage processing. These contaminants are found in many commonly consumed items, such as fermented food products and alcoholic beverages, and baked and fried foods. With a head office in Vancouver, Functional Technologies Corp. has R&D operations in Prince Edward Island and Europe, as well as a U.S. sales office in Napa Valley, California. For more information, please visit our website at .

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.



Contacts:
Functional Technologies Corp.
Connie Chen, PhD
VP, Corporate Development and Communications
+1.647.282.5038




Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Pacgen Reports Annual Financial Results
Corcept Therapeutics Announces Second Quarter Results and Corporate and Development Update
Bereitgestellt von Benutzer: MARKET WIRE
Datum: 08.08.2011 - 05:00 Uhr
Sprache: Deutsch
News-ID 1028233
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

VANCOUVER, BRITISH COLUMBIA


Phone:

Kategorie:

Biotech


Anmerkungen:


Diese Pressemitteilung wurde bisher 158 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Functional Technologies Grants Options
"
steht unter der journalistisch-redaktionellen Verantwortung von

Functional Technologies Corp. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Functional Technologies Corp.



 

Who is online

All members: 10 563
Register today: 0
Register yesterday: 2
Members online: 0
Guests online: 76


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.